Search
GU Cancer
NRG GU006
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
AGCT 1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
EA8153 (NCT03419234)
Cabazitaxel with Abiraterone versus Abiraterone Alone: A Randomized Trial for Extensive Disease in Prostate Cancer Following Docetaxel: The CHAARTED2 Trial
NRG-GU005 (NCT03367702)
Phase III IGRT and SBRT versus IGRT and Hypofranctionated IMRT for Localized Intermediate Risk Prostate Cancer
A031501
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
S1605 (NCT02844816)
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NRG RTOG 0924 (NCT01368588)
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
SWOG S1500 (NTC02751057)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
MATCH: EAY131 (NCT02465050)
MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.
